

PRDM16 (174A2D): sc-517625

BACKGROUND

The PR-domain containing proteins (PRDMs) have a common involvement in the modulation of gene activities. A PR-domain family member usually produces two products, called PR-plus and PR-minus, which differ by the presence or absence of the PR domain, respectively. The PR-plus product is underexpressed or disrupted in cancer cells, whereas the PR-minus product is present or overexpressed in cancer cells. This imbalance in the amount of the two products, which is a result of either genetic or epigenetic events, appears to be a determining factor of malignancy. PRDM16 (PR domain containing 16), also known as MEL1 or PFM13, is a 1,276 amino acid protein that contains one SET domain and ten C₂H₂-type zinc fingers. Localized to the nucleus, PRDM16 functions as a transcription factor and is thought to be involved in the pathogenesis of acute myeloid leukemia and myelodysplastic syndrome. Three isoforms of PRDM16 exist due to alternative splicing events.

REFERENCES

1. Mochizuki, N., et al. 2000. A novel gene, MEL1, mapped to 1p36.3 is highly homologous to the MDS1/EVI1 gene and is transcriptionally activated in t(1;3)(p36;q21)-positive leukemia cells. *Blood* 96: 3209-3214.
2. Nishikata, I., et al. 2003. A novel EVI1 gene family, MEL1, lacking a PR domain (MEL1S) is expressed mainly in t(1;3)(p36;q21)-positive AML and blocks G-CSF-induced myeloid differentiation. *Blood* 102: 3323-3332.
3. Xinh, P.T., et al. 2003. Breakpoints at 1p36.3 in three MDS/AML(M4) patients with t(1;3)(p36;q21) occur in the first intron and in the 5' region of MEL1. *Genes Chromosomes Cancer* 36: 313-316.
4. Lahortiga, I., et al. 2004. Molecular characterization of a t(1;3)(p36;q21) in a patient with MDS. MEL1 is widely expressed in normal tissues, including bone marrow, and it is not overexpressed in the t(1;3) cells. *Oncogene* 23: 311-316.
5. Ott, M.G., et al. 2006. Correction of X-linked chronic granulomatous disease by gene therapy, augmented by insertional activation of MDS1-EVI1, PRDM16 or SETBP1. *Nat. Med.* 12: 401-409.
6. Seale, P., et al. 2007. Transcriptional control of brown fat determination by PRDM16. *Cell Metab.* 6: 38-54.
7. Roche-Lestienne, C., et al. 2008. RUNX1 DNA-binding mutations and RUNX1-PRDM16 cryptic fusions in Bcr-Abl + leukemias are frequently associated with secondary trisomy 21 and may contribute to clonal evolution and imatinib resistance. *Blood* 111: 3735-3741.
8. Modlich, U., et al. 2008. Leukemia induction after a single retroviral vector insertion in Evi1 or PRDM16. *Leukemia* 22: 1519-1528.
9. Seale, P., et al. 2008. PRDM16 controls a brown fat/skeletal muscle switch. *Nature* 454: 961-967.

CHROMOSOMAL LOCATION

Genetic locus: PRDM16 (human) mapping to 1p36.32.

STORAGE

Store at 4° C, **DO NOT FREEZE**. Stable for one year from the date of shipment. Non-hazardous. No MSDS required.

SOURCE

PRDM16 (174A2D) is a mouse monoclonal antibody raised against a recombinant protein corresponding to amino acids 779-996 of PRDM16 of human origin.

PRODUCT

Each vial contains 100 µg IgG₁ kappa light chain in 1.0 ml of PBS with < 0.1% sodium azide and 0.1% gelatin.

APPLICATIONS

PRDM16 (174A2D) is recommended for detection of PRDM16 of human origin by Western Blotting (starting dilution 1:200, dilution range 1:100-1:1000).

Suitable for use as control antibody for PRDM16 siRNA (h): sc-62854, PRDM16 shRNA Plasmid (h): sc-62854-SH and PRDM16 shRNA (h) Lentiviral Particles: sc-62854-V.

Molecular Weight of PRDM16: 140 kDa.

RECOMMENDED SUPPORT REAGENTS

To ensure optimal results, the following support reagents are recommended:
1) Western Blotting: use m-IgGκ BP-HRP: sc-516102 or m-IgGκ BP-HRP (Cruz Marker): sc-516102-CM (dilution range: 1:1000-1:10000), Cruz Marker™ Molecular Weight Standards: sc-2035, UltraCruz® Blocking Reagent: sc-516214 and Western Blotting Luminol Reagent: sc-2048.

RESEARCH USE

For research use only, not for use in diagnostic procedures.

PROTOCOLS

See our web site at www.scbt.com for detailed protocols and support products.